New mRNA Malaria Vaccine Shows 95% Efficacy in Phase 3 Trial Across 6 African Countries
An mRNA-based malaria vaccine developed by Oxford and BioNTech has demonstrated 95% efficacy in a Phase 3 trial involving 22,000 children across six African nations, far surpassing existing vaccines and offering hope for eliminating the disease.